Cash balance of $16.4 million as at September 30, 2023Revenue of $1.0 million (vs 2022: $0.7 million, an increase of 33.5%)Gross profit of $0.4 million (vs 2022... Read More...
Cash balance of $17.5 million as at June 30, 2023Revenue of $1.2 million (vs 2022: $0.8 million, an increase of 53.1%)Gross profit of $0.5 million (vs 2022: $0.... Read More...
VANCOUVER, British Columbia, Aug. 14, 2023 -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company engineering the next wav... Read More...
- Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2 efficacy data for CYB003 and Phase 1 data for CYB004 -- U.S. Food and Drug Administra... Read More...
Cash balance of $18.5 million as at March 31, 2023Revenue of $3.95 million (vs 2022: $2.3 million, an increase of 69.8%)Gross profit of $1.7 million (vs 2022: $... Read More...
VANCOUVER, BC, June 29, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and sa... Read More...
COMPASS PathwaysLONDON, May 03, 2023 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-b... Read More...
Toronto, Ontario--(Newsfile Corp. - April 25, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an O... Read More...
Q2 2023 revenues grew 581.1% year-over-year to $5.4 million
Q2 2023 gross margin increased to 39.3% from 29.1% in Q2 2022
Gross profit of $2.1 million, increas... Read More...
VANCOUVER, BC, March 30, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and s... Read More...
- Company to provide CYB003 Phase 1/2a interim study readout and update on its CYB004 program at upcoming R&D Day on February 28, 2023 -This news release co... Read More...
Q1 2023 revenues grew 618% year-over-year to $5.7 million
Q1 2023 gross margin grew to 41.9% from 31.5% in prior quarter
Gross profit of $2.4 million, an incre... Read More...
Cash balance of $20.5 million as at September 30, 2022Revenue of $736 thousand (2021 - $485 thousand)Property and equipment value of $4.7 millionTotal assets of... Read More...
Q4 2022 revenues grew 643% year-over-year to $4.2 million
Q4 2022 gross margin grew to 31.5%, generated $1.3 million of gross profit
Completed acquisition of ... Read More...
TORONTO, Nov. 28, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" of “Field Trip”), a global leader in the delivery of psychedelic the... Read More...
Appoints Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative HealthSchedules Fiscal Second Quarter 20... Read More...
DENVER, Nov. 14, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company aiming to transform the treatment... Read More...
COMPASS PathwaysLONDON, Oct. 26, 2022 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-... Read More...
Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine micr... Read More...
Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments New Marketing Programs Showing Encouraging Early Results OXNARD, Calif., Sept. ... Read More...
Cash balance of $23.0 million as at June 30, 2022Revenue of $785 thousandProperty and equipment value of $4.8 millionTotal assets of $32.7 millionToronto, Ontar... Read More...
Completed corporate reorganization on August 11, 2022 separating the drug development (“Reunion Neuroscience Inc.” or “Reunion”) and healthcare and wellness (“F... Read More...
TORONTO, Aug. 23, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a global leader in psychedelic therapies, announce... Read More...
Toronto, Ontario--(Newsfile Corp. - August 18, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announces today that the Company ... Read More...
DENVER, Aug. 15, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company aiming to transform the treatment... Read More...
COMPASS PathwaysLONDON, Aug. 04, 2022 --Highlights:Kabir Nath appointed as Chief Executive Officer Phase III program submitted to FDA and under reviewCOMP360 ph... Read More...
COMPASS PathwaysLONDON, July 26, 2022 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-... Read More...
Revenues grew 32% year-over-year to $0.74 million for the quarter
Clinic network revenues grew 59.5% from the same quarter last year and 7.5% compared to prior... Read More...
Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.Ea... Read More...
TORONTO, June 22, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedel... Read More...
DENVER, May 16, 2022 -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to tr... Read More...
COMPASS PathwaysLONDON, May 03, 2022 -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-b... Read More...
VANCOUVER, BC, May 3, 2022 - Delic Holdings Corp ("DELIC" or the "Company") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for ... Read More...
VANCOUVER, BC, April 26, 2022 - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE") today announced its financial results for the three and... Read More...
Revenues grew 240% year-over-year to $0.8 million for the quarter
Achieved 29.1% gross margin during Q2 2022, compared to 6.5% in Q1 2022, due to a larger prop... Read More...
